MAPK3 and non-small cell lung carcinoma: Gefitinib, in combination with lovastatin effectively downregulated ras protein and suppressed Raf, ERK1/2, Akt, and EGFR phosphorylation in gefitinib-resistant A549 and NCI-H460 human NSCLC cells [12].